Colorectal cancer: Current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation

Table 1 Summary of studies with measurement of hepatic transit times in subjects with and without the evidence of liver metastases

		Hepatic transit time (arterial to venous) (s)
Study	Number of patients	Livermetastases	No liver metastases	contrast agent	mod-ality
Bernatik et al[73]	28/36	6.7	15.4	Optison1	CEUS
Hohmann et al[10]	22/22	7.4	11.1	SonoVue2	CEUS
Zhang et al[71]	5/3	6.2	11.3	SonoVue2	CEUS
Haendl et al[72]	20/15	6.3	9.3	SonoVue2	CEUS
Haendl et al[72]	12/14	9.9	14.8	Levovist3	CEUS
Haendl et al[72]	20/15	6.3	9.2	Luminity4	CEUS
Hohmann et al[78]	20/21	7.1	13.5	MultiHance2	MRI

¹Amersham, Little Chalfont, United Kingdom;

²Bracco, Milano, Italy;

³Bayer, Berlin, Germany;

⁴Lantheus, N. Billerica, MA, United States. These are mainly studies using CEUS but also one study which used MRI. All other MRI studies used slightly different approaches and did not measure directly comparable values. CEUS: Contrast enhanced ultrasound; MRI: Magnetic resonance imaging.